New AI tool could spot hidden prostate cancers on MRI
NCT ID NCT05710380
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This study is testing a new software tool that automatically analyzes MRI images of the prostate to find cancer areas that might be missed by doctors. About 180 people with known or suspected prostate cancer will have an MRI and then a targeted biopsy. The goal is to see if the software can help improve cancer detection accuracy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Risk Map Decision Support System (DSS) software
What this could lead to
If successful, this tool could help doctors detect prostate cancer more accurately, reducing missed cancers during biopsies.
What could go wrong
This is an early-stage study with only 180 participants. The software may not prove more accurate than standard methods, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.